Best Practice & Research Clinical Haematology
Volume 22, Issue 3 , Pages 295-302 , September 2009

Epidemiology of chronic myeloid leukaemia (CML)

  • Maren Rohrbacher (Doctor of Medicine)

      Affiliations

    • III. Medizinische Universitätsklinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Wiesbadener Straße 7–11, 68305 Mannheim, Germany
    • ,
  • Joerg Hasford (Professor and Doctor of Medicine)

      Affiliations

    • Institut für Med. Informationsverarbeitung, Biometrie und Epidemiologie, Ludwig-Maximilians Universität München, Marchioninistr.15, 81377 München, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49 89 7095 7480; Fax: +49 89 7095 7482.

References 

  1. Hehlmann R, Hochhaus A, Baccarani M. Chronic myeloid leukaemia. Lancet. 2007;370:342–350
  2. Parkin DM. The evolution of the population-based cancer registry. Nat Rev Cancer. 2006;6:603–612
  3. Swedish Cancer Registry . Annual report publications of the centre of epidemiology at the National Board of Health and Welfare. Available from: http://www.socialstyrelsen.se/Statistik/statistik_amne/Cancer1998–2006;
  4. Krebsregister Saarland, Germany. Available from: http://www.krebsregister.saarland.de
  5. Ries LAG, Melbert D, Krapcho M, et al. SEER cancer statistics review. Available from: Bethesda: U.S. National Cancer Institute; 1975–2005;http://www.seer.cancer.gov/csr/1975_2005
  6. Micheli A, Coebergh JW, Mugno E, et al. European health systems and cancer care. Ann Oncol. 2003;14(Suppl. 5):v41–v60
  7. Phekoo KJ, Richards MA, Moller H, et al. The incidence and outcome of myeloid malignancies in 2112 adult patients in southeast-England. Haematologica- Hematol J. 2006;91:1400–1404
  8. Harrison SJ, Johnson PRE, Holyoake TL. The Scotland leukaemia registry audit of incidence, diagnosis and clinical management of new patients with chronic myeloid leukaemia in 1999 and 2000. Scott Med J. 2004;49:87–90
  9. McNally RJ, Rowland D, Roman E, et al. Age and sex distributions of hematological malignancies in the U.K. Hematol Oncol. 1997;15:173–189
  10. Rohrbacher M, Berger U, Hochhaus A, et al. Clinical trials underestimate age of chronic myeloid leukemia (CML) Patients. Incidence and median age of Ph/BCR-ABL positive CML and other chronic myeloproliferative disorders in a representative area in Germany. Leukemia. 2008;23:602–604
  11. Hasford J, Tauscher M, Hochhaus A, et al. Incidence, co-morbidity and treatment survey of chronic myeloid leukemia in Germany. (ASH Annual Meeting Abstracts) Blood. 2007;110:[Abstract 2964]
  12. Corm S, Micol J, Leroyer A, et al. Kinetic of chronic myeloid leukaemia (CML) prevalence in Northern France since the introduction of imatinib. J Clin Oncol. 2008;26:[May 20 Suppl; Abstract 7088]
  13. Ahmad O, Boschi-Pinto C, Lopez A, et al. Age standardization of rates: a new WHO standard. GPE discussion paper series: no. 31. Available from: http://www.who.int/infobase/help[accessed 08.04.08]
  14. Ridell B, Carneskog J, Wedel H, et al. Incidence of chronic myeloproliferative disorders in the city of Göteborg, Sweden 1983–1992. Eur J Haematol. 2000;65:267–271
  15. Hasford J, Baccarani M, Hehlmann R, et al. Interferon-a and hydroxyurea in early chronic myeloid leukemia: a comparative analysis of the Italian and German chronic myeloid leukemia trials with interferon-a. Blood. 1996;88:5384–5391
  16. Allan NC, Richards SM, Shepherd PC. UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's working parties for therapeutic trials in adult leukaemia. Lancet. 1995;345:1392–1397
  17. Micheli A, Mugno E, Krogh V, et al. Cancer prevalence in European registry areas. Ann Oncol. 2002;13:840–865
  18. Tardieu S, Brun-Strang C, Berthaud P, et al. Management of chronic myeloid leukemia in France: a multicentered cross-sectional study on 538 patients. Pharmacoepidemiol Drug Saf. 2005;14:545–553
  19. Verdecchia A, Baili P, Quaglia A, et al. Patient survival for all cancers combined as indicator of cancer control in Europe. Eur J Public Health. 2008;18:527–532
  20. Micheli A, Capocaccia R, Martinez C, et al. Cancer control in Europe: a proposed set of European cancer health indicators. Eur J Public Health. 2003;13:116–118
  21. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia. Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108:1809–1820
  22. Kantarjian HM, Cortes J, Guilhot F, et al. Diagnosis and management of chronic myeloid leukemia: a survey of American and European practice patterns. Cancer. 2007;109:1365–1375
  23. Michallet M, Morra E, Steegmann J, et al. Imatinib resistance and/or intolerance in clinical practice in Europe: the “Unmet needs in CML and Ph+ALL” (UNIC) study. (ASH Annual Meeting Abstracts) Blood. 2007;110:[Abstract 1951]
  24. Morra E, Michallet M, Steegmann J, et al. Real-life rates of disease monitoring in clinical practice in Europe: the “Unmet needs in CML and Ph+ALL” (UNIC) Study. (ASH Annual Meeting Abstracts) Blood. 2007;110:[Abstract 1959]
  25. “It`s best to test” survey: an assessment of CML monitoring across Europe. This survey was conducted between November 2007 and February 2008 by the independent market research agency TNS and funded by Bristol-Myers Squibb. Bristol-Myers Squibb, 2008.
  26. Cortes J, Talpaz M, O'Brien S, et al. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer. 2003;98:1105–1113
  27. Rosti G, Iacobucci I, Bassi S, et al. Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML working party. Haematologica. 2007;92:101–105
  28. Hehlmann R, Heimpel H, Hasford J, et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood. 1994;84:4064–4077
  29. Baccarani M, Rosti G, De Vivo A, et al. A randomized study of interferon-alpha versus interferon-alpha and low- dose arabinosyl cytosine in chronic myeloid leukemia. Blood. 2002;99:1527–1535
  30. Bonifazi F, De Vivo A, Rosti G, et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood. 2001;98:3074–3081
  31. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408–2417
  32. Guilhot F, Chastang C, Michallet M, et al. Interferon alpha2b (IFN) combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med. 1997;337:223–229
  33. Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for the survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst. 1998;90:850–858
  34. Hehlmann R, Berger U, Pfirrmann M, et al. Randomized comparison of Interferon-a and Hydroxyurea with Hydroxyurea monotherapy in Chronic Myeloid Leukemia (CML-Study II): prolongation of survival by the combination of Interferon-a and Hydroxyurea. Leukemia. 2003;17:1529–1537
  35. Hehlmann R, Berger U, Pfirrmann M, et al. Drug treatment is superior to allografting as first line therapy in chronic myeloid leukemia. Blood. 2007;109:4686–4692
  36. Ohnishi K, Ohno R, Tomonaga M, et al. A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood. 1995;86:906–916
  37. The Italian Cooperative Study Group on Chronic Myeloid Leukemia . Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med. 1994;330:820–825
  38. The Benelux CML Study Group . Randomized study on hydroxyurea alone versus hydroxyurea combined with low-dose interferon-a2b for chronic myeloid leukemia. Blood. 1998;91:2713–2721
  39. Kluin-Nelemans HC, Buck G, Le Cessie S, et al. Randomized comparison of low-dose versus high-dose interferon-alfa in chronic myeloid leukemia: prospective collaboration of 3 joint trials by the MRC and HOVON groups. Blood. 2004;103:4408–4415
  40. Kantarjian HM, Talpaz M, O'Brien S, et al. Survival benefit with imatinib mesylate versus interferon alpha-based regimens in newly diagnosed chronic phase chronic myelogenous leukemia. Blood. 2006;108:1835–1840
  41. Xie Y, Davies SM, Xiang Y, et al. Trends in leukemia incidence and survival in the United States (1973–1998). Cancer. 2003;97:2229–2235
  42. Berger U, Maywald O, Pfirrmann M, et al. Gender aspects in chronic myeloid leukemia: long-term results from randomized studies. Leukemia. 2005;19:984–989

PII: S1521-6926(09)00040-1

doi: 10.1016/j.beha.2009.07.007

Best Practice & Research Clinical Haematology
Volume 22, Issue 3 , Pages 295-302 , September 2009

Article Tools

* Image Usage & Resolution